Hims & Hers Health Target of Unusually High Options Trading (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually large options trading on Monday. Stock traders purchased 67,660 call options on the stock. This is an increase of 52% compared to the average volume of 44,492 call options.

Hims & Hers Health Trading Up 23.9 %

Shares of HIMS opened at $31.39 on Tuesday. Hims & Hers Health has a 12-month low of $8.09 and a 12-month high of $31.40. The company has a market cap of $6.86 billion, a PE ratio of 71.34 and a beta of 1.06. The stock has a 50-day moving average price of $20.85 and a 200-day moving average price of $19.44.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.04) earnings per share. As a group, analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 58,750 shares of Hims & Hers Health stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $21.04, for a total value of $1,236,100.00. Following the transaction, the chief operating officer now owns 630,166 shares in the company, valued at $13,258,692.64. The trade was a 8.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. The trade was a 84.94 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,049,183 shares of company stock valued at $21,395,632. 17.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors have recently bought and sold shares of the stock. Sei Investments Co. increased its position in shares of Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after acquiring an additional 37,890 shares during the period. Vanguard Group Inc. raised its position in Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after purchasing an additional 136,907 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Hims & Hers Health by 239.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 168,427 shares of the company’s stock worth $2,606,000 after buying an additional 118,848 shares during the period. SVB Wealth LLC bought a new stake in shares of Hims & Hers Health in the 1st quarter worth approximately $421,000. Finally, Bayesian Capital Management LP purchased a new position in shares of Hims & Hers Health during the first quarter valued at approximately $1,770,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HIMS has been the subject of a number of research reports. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.71.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.